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Diabetic macular edema (DME) is arguably 
one of the most important challenges in 
ophthalmology. Macular edema refractory 
to laser photocoagulation remains the most 
prevalent cause of untreatable vision loss in 
diabetes and is responsible for visual disability 
in millions of people worldwide. The lack of an 
effective therapeutic solution accounts for the 
range of interventions proposed. These include 
intraocular delivery of corticosteroids and anti-
VEGF antibodies, and the surgical alternative 
of vitrectomy with or without removal of the 
internal limiting membrane (ILM). In this issue 
of Journal of Ophthalmic & Vision Research, 
Dehghan and co-authors1 present the results 
of a prospective interventional case series of 
triamcinolone-assisted vitrectomy with ILM 
peeling for refractory diffuse non-tractional 
DME. They found no significant effect on 
visual acuity despite a reduction in mean 
macular thickness. The publication of studies 
such as this helps redress the biases that tend 
to promote the reporting and publication of 
positive findings. This study also illustrates 
the challenges associated with designing an 
experiment that will allow clear conclusions 
to be drawn about the value of combination 
treatments in such a complex condition.
A number of series have suggested that 
vitrectomy alone can improve macular function 
in DME. The rationale for this approach 
involves relief of mechanical tangential or 
antero-posterior tractional forces associated 
with a taut thickened posterior hyaloid at the 
macula. There is consensus that DME associated 
with such traction, evident on biomicroscopy 
or optical coherence tomography (OCT), can 
benefit from vitrectomy with removal of the 
attached posterior hyaloid membrane. Removal 
of the ILM, which can itself be thickened in 
diabetic eyes, has been proposed as an additional 
procedure to ensure complete removal of 
cortical vitreous, and to reduce the likelihood 
of subsequent epiretinal membrane formation 
by inhibiting migration and reproliferation of 
astrocytes.
Whether vitrectomy can improve vision in 
eyes with DME but no evidence of vitreomacular 
traction, however, has not been established. 
The rationale for vitrectomy in this context 
is certainly less obvious but possible benefits 
include improved retinal oxygenation by 
promotion of intraocular fluid currents, and 
relief of any subclinical tractional forces. Removal 
of the ILM in non-tractional refractory DME 
might favorably alter hydrostatic forces across 
the inner retina and/or stimulate beneficial, 
if short-lived, inflammatory responses. Few 
studies have been able to determine with 
confidence the efficacy and adverse effects 
of these interventions and we have to rely 
on non-randomized and poorly controlled 
case series that are frequently confounded by 
the adjunctive use of triamcinolone and/or 
macular photocoagulation. However, a recent 
randomized controlled trial of vitrectomy with 
either ILM peeling or intravitreal triamcinolone 
for diffuse non-tractional DME by Figueroa and 
coworkers2 identified no sustained anatomical 
or functional improvement. In their report, 
Dehghan et al1 describe their experience with 
vitrectomy and ILM peeling in similar eyes. 
They acknowledge that the adjunctive use of 
triamcinolone could have contributed to the 
observed outcome, and the lack of a control 
group means that the results cannot be compared 
with the natural course of the condition or any 
standard treatment. Despite these limitations, 
however, their conclusions are consistent with 
those of Figueroa et al in identifying no clear 
benefit in terms of visual acuity. The weight of 
available evidence suggests that vitrectomy for 
non-tractional DME does not offer significant 
benefit in terms of visual acuity, regardless of Editorial; Bainbridge
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whether the ILM is removed.
Dehghan et al highlight in their work a 
discrepancy between anatomical and functional 
results, one that is frequently apparent 
following interventions for DME. Studies on 
both vitrectomy and local administration of 
corticosteroids have consistently identified a 
significant reduction in retinal thickness with no 
detectable or minimal benefit on visual acuity 
in many eyes. While this discrepancy might be 
explained in some series by the development 
of cataract, similar findings in pseudophakic 
eyes question the extent to which the functional 
deficit in DME is reversible. In the near future, 
we can expect that developments in structural 
and functional retinal imaging will facilitate 
a more detailed characterization of macular 
disease and address this question with a better 
understanding of the impact of therapeutic 
interventions. For example, spectral domain 
high-resolution OCT is likely to help identify 
eyes in which thickening of the posterior hyaloid 
and ILM could respond favorably to surgical 
intervention more reliably and at an early stage 
of the disease. Multispectral imaging will enable 
non-invasive characterization of cellular and 
molecular processes in DME to help clarify its 
pathogenesis and develop better treatments.
We should continue to question our narrow 
focus on visual acuity as a sole outcome 
measure of macular function. Other techniques 
such as microperimetry and multifocal 
electroretinography together with visual 
function questionnaires can provide highly 
relevant information that could more sensitively 
detect changes in macular function than can 
be demonstrated by testing visual acuity alone. 
With the benefit of better insight into the 
relationship between macular structure and 
function we can hope to intervene promptly and 
effectively, with the aim of making refractory 
DME a thing of the past.
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